New rating for NorthX Biologics in International Sustainability Survey

New rating for NorthX Biologics in International Sustainability Survey

We are proud to inform you that NorthX Biologics improved its score from bronze to silver in the International Sustainability Survey (EcoVadis) for the year 2022. We have also implemented more routines and policies at our company to continuously improve the way we operate.

EcoVadis provides holistic sustainability rating services of companies. The rating covers a broad range of non-financial management systems including environmental, labor & human rights, ethics, and sustainable procurement impacts. NorthX has been rated on the material issues that are relevant to our company’s size, location, and industry.

It is important as a company to manage sustainability risks, and the Pharma industry is no exception. Our goal is to provide sustainable process development and manufacturing services at our company.

If we look closer at the environmental area, we have improved our preventive work such as decreasing our impact on the environment and the municipality’s treatment plant. We now know more about the characteristics of our wastewater and how to handle our hazardous waste which gives us a better chance to improve and become more sustainable.

In the ethics area, we also have improved our preventative work such as implementing policies on information security, ethics issues and corruption. It is important to us that we also have a sustainable production and use raw materials that have been ethically made.

It is also important for us to have good work health and equality. At NorthX we have good diversity, equity, and inclusion of all employees. It is important that our employees stay safe and healthy for a sustainable workplace. We do preventive workthrough risk assessment, information sharing, and education.

We thank all of our employees for the work they have done for this rating and look forward to continuing our improvements in these areas in order to progress in the survey.

Gene Therapy For Rare Disorders- March 20th-23rd

Gene Therapy For Rare Disorders- March 20th-23rd

March 20th-23rd

Gene Therapy For Rare Disorders

The 6th Annual Gene Therapy for Rare Disorders 2023 Summit remains devoted to showcasing the top case studies and strategic learnings from the past year. With an expert speaking faculty devoted to bringing safer and more effective gene therapies to rare disease patients, key questions will be answered on how best the field can overcome regulatory, clinical, manufacturing and pricing bottlenecks to progress gene therapies into and through the clinic. Book a meeting with us here!

Advanced Therapies Week- January 17th-20th 2023

Advanced Therapies Week is an event like no other.

With networking opportunities taking place from morning to night, we provide attendees with an outstanding experience that entails thought-provoking content, high-profile speakers, and unmissable networking events. We bring together the advanced therapies field in the most memorable way, and we guarantee you’ll want to be involved.  Book a meeting with us here!

Advanced Biologics in Matfors and Beyond

Advanced Biologics in Matfors and Beyond

Conference “Advanced Biologics in Matfors and Beyond” at NorthX Bio went to a big success!

During a two day conference, a number of key stakeholders from the Swedish and Danish ecosystem visited the Matfors site of NorthX Biologics. The highlight of the tour being the walk about in our GMP licenced facility for ATMP manufacturing as well as the brand new innovation area, delegates also valued the discussions as such. How important it is not least for the government to know we have such capacity on Swedish territory. Yet, from a business perspective of NorthX, the importance to reach beyond the Nordics to showcase how biotechs can use this capacity.  

As the conference was such a success, with a waiting list for those that we could not fit, we are already planning for a follow up! Stay tuned.

Photo: the panel visiting the new facility at Matfors.
Xintela and NorthX Biologics sign framework agreement for collaboration

Xintela and NorthX Biologics sign framework agreement for collaboration

Xintela and NorthX Biologics announce that they have signed a collaborative framework agreement to jointly accelerate the development of advanced therapeutics (ATMP) by leveraging the companies’ complementary skills and resources in ATMP development and GMP manufacturing. Projects to be initiated within the framework of the collaboration include, among other things, product and process development, quality control and increased expansion capacity for manufacturing ATMPs.

“This is a very interesting opportunity for us. Xintela has developed the unique stem cell product XSTEM, which is now in clinical development, and has strong expertise in process development and GMP manufacturing of stem cells and other ATMPs. Together with NorthX Biologics and their manufacturing capacity, we can further expand and also broaden our ATMP business”, says Evy Lundgren-Åkerlund, CEO of Xintela.
“This collaboration is another step in the right direction towards becoming a leading solution provider in the cell and gene therapy space, adding to the solid expertise NorthX has already gained from +30 years of advanced biological GMP manufacturing. I am happy to work with Xintela and look forward to our relationship going forward,” says Helena Strigård, CEO of NorthX Biologics.

Xintela and NorthX Biologics sign framework agreement for collaboration
Xintela and NorthX Biologics sign framework agreement for collaboration